Loading organizations...
BlueSkeye AI is a Nottingham, United Kingdom-based software company that develops artificial intelligence technology to analyze facial expressions, voice behavior, and human emotions using standard mobile devices. The company provides software development kits, including the B-Social and B-Automotive SDKs, which enable emotion detection and behavioral analysis for commercial applications in mental health monitoring, social robotics, and in-vehicle driver monitoring. Operating as a technology spin-out from the University of Nottingham, the firm supplies its clinical-grade artificial intelligence platforms to automotive manufacturers and healthcare organizations, including the Nottinghamshire NHS Trusts. The organization recently launched its Health Foundation Platform at the CES 2024 technology trade show and currently supports a user base of approximately 250,000 individuals utilizing its specialized maternal mental health monitoring technology. BlueSkeye AI was originally founded in April 2019 by Michel Valstar, Timur Almaev, and Tosh Brown.
BlueSkeye AI has raised $4.0M across 1 funding round.
BlueSkeye AI has raised $4.0M in total across 1 funding round.
BlueSkeye AI has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in October 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2022 | $4M Seed | — | Insight Partners, Left Lane Capital, Remus Capital, Scale Asia Ventures, Scalebridge Capital | Announced |
BlueSkeye AI has raised $4.0M in total across 1 funding round.
BlueSkeye AI's investors include Insight Partners, Left Lane Capital, REMUS Capital, Scale Asia Ventures, Scalebridge Capital.
Blueskeye AI is a technology company that develops software-only SDKs using machine learning to objectively measure social, emotional, and medically relevant expressed behaviors from face and voice data, delivering real-time insights more accurately than humans.[1][2][3] It serves industries including health & wellbeing, automotive, social robotics, and FMCG by providing clinical-grade tools for applications like patient monitoring, intelligent cockpits, empathetic robots, and consumer research, solving the problem of subjective human assessment with ethical, hardware-agnostic AI that runs on existing devices like mobile phones and tablets.[1][2][3] As a 2019 University of Nottingham spin-out, it raised £3.4m in venture funding led by XTX Ventures in 2022, demonstrating strong growth momentum through deployments, ISO 27001 certification, EU AI Act and GDPR compliance, and ongoing clinical trials.[1][3]
Blueskeye AI was incorporated on 18 April 2019 as a private limited company (number 11953581) and spun out from The University of Nottingham’s School of Computer Science to commercialize over 22 years of research in human behavior understanding, particularly in machine learning, computer vision, facial expression analysis, affective computing, and social signal processing.[1][3][4] Co-founder and CTO Professor Michel Valstar, with a PhD and 22 years in the field (cited over 19,000 times across 150+ peer-reviewed publications), led the academic groundwork; another co-founder holds a PhD in Computer Science focused on edge computing and privacy-preserving AI, with 10+ years in software engineering.[1] CEO Steve Cliffe, a serial tech entrepreneur with global experience in marketing, sales, and business scaling across Europe, North America, and Asia, joined to drive commercialization; the leadership emphasizes strategic thinking, negotiation, and purpose-driven team guidance.[1] Early traction included the 2022 £3.4m funding round led by XTX Ventures, enabling product launches like B-Automotive and B-Social SDKs.[1]
Blueskeye AI rides the wave of Emotion AI and affective computing, enabling machines to interpret human emotions and behaviors ethically at scale amid rising demand for personalized, data-driven experiences in health, mobility, and human-machine interaction.[1][2][3] Timing aligns with regulatory shifts like the EU AI Act and growing edge AI adoption, where lightweight models process sensitive data on-device to meet privacy standards—critical as automotive OEMs push "smart cockpits" and healthcare seeks objective biomarkers beyond subjective clinician assessments.[3] Market forces favoring it include the explosion of in-cabin monitoring (for safety and loyalty), telehealth post-pandemic, and empathetic robotics for aging populations or retail; its Nottingham roots and clinical validation position it to influence ecosystems by providing trusted SDKs that OEMs, Tier 1 suppliers, and app developers integrate, accelerating AI trustworthiness across sectors.[2][3]
Blueskeye AI is poised to expand its SDK ecosystem with deeper automotive integrations (e.g., next-gen occupant health monitoring) and health trials yielding new biomarkers, fueled by its funding and compliance edge.[1][3] Trends like pervasive edge AI, multimodal sensing (face+voice), and AI ethics regulations will amplify its growth, potentially capturing leadership in Emotion AI as vehicles and devices become proactive wellness companions. Its influence may evolve from niche innovator to ecosystem enabler, powering safer, more empathetic tech—reinforcing its mission to make ethical mind-measuring ubiquitous, starting from that pivotal 2019 spin-out.[1][2]
